According to statistical data, the miRNA drug market was estimated at approximately $160.5 million in 2017, with an expected compound annual growth rate (CAGR) of 18.6%.

Monte Rosa Therapeutics has signed a worldwide licensing deal with Novartis to promote VAV1-targeted molecular glue degraders that modulate T and B cells.

Merck and Moderna have begun a Phase 3 study to assess V940 (mRNA-4157) with KEYTRUDA® (pembrolizumab).

Lilly’s mirikizumab is the first and only IL23p19 antagonist to provide long-term safety and efficacy data over several years for ulcerative colitis and Crohn’s disease.

AstraZeneca’s Fasenra (benralizumab) has received approval in the EU as a supplementary therapy for adults dealing with relapsing or refractory eosinophilic granulomatosis with polyangiitis.

Celldex Reports Barzolvolimab Successfully Achieved All Main and Secondary Goals with Strong Statistical Significance in Positive Phase 2 Trial for Chronic Inducible Urticaria.

Biogen shares promising findings from the Phase 2 IGNAZ trial of Felzartamab for IgA nephropathy during Kidney Week 2024 hosted by the American Society of Nephrology (ASN).

Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference.

As a cutting-edge therapeutic approach, antisense oligonucleotide drugs precisely target the mRNA or pre-mRNA of disease-causing genes.

Jubilant Therapeutics Inc. has reported the initial dosing of patients in worldwide clinical trials for JBI-802, a CoREST inhibitor, and JBI-778, a PRMT5 inhibitor.

Otsuka Pharmaceutical announced positive top-line interim data from the phase III clinical trial of sibeprenlimab for treating adults with IgA nephropathy.

Maze Therapeutics announces encouraging initial human data from a Phase 1 trial involving healthy participants.